Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Case report: Ectopic production of intact parathyroid hormone (iPTH) by malignoma mimicking primary hyperparathyroidism.
Front Oncol
December 2024
Department of Nephrology, St. Georg Hospital, Leipzig, Germany.
Background: Malignant hypercalcemia is usually caused by osteolytic processes of metastases, production of parathormone-related peptide, or secretion of 1,25-dihydroxyvitamin D. Ectopic PTH (parathyroid hormone) production by malignancy is very unusual.
Methods: Case report and review of the literature.
Adolescent Hyperparathyroidism: An Updated Contemporary Surgical Experience at a Tertiary Center.
J Surg Res
December 2024
Department of Surgery, University of Chicago Medicine, Chicago, Illinois.
Introduction: Primary hyperparathyroidism (pHPT) in children is uncommon, resulting in a paucity of data describing the disease process in this population. Herein, in an effort to bridge the information gap, we review our experience with pHPT in adolescent patients under 20 y of age at a specialized tertiary referral center.
Methods: A retrospective chart review included all adolescent patients with pHPT, who underwent surgery at our institution between 2004 and 2023.
Same-day parathyroidectomy for primary hyperparathyroidism -an over 20-year practice.
World J Surg
December 2024
Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Introduction: There has been a shift in recent years toward same-day parathyroidectomies due to the decrease in mutual costs with few significant differences in postoperative morbidity or mortality. We sought to determine if demographics, preoperative patient risk factors, or comorbidities were associated with a patient's likelihood of having same-day or inpatient surgery.
Materials And Methods: A prospective database of parathyroid operations from 2001 to 2022 (n = 2948 patients) was reviewed for surgeries completed for primary hyperparathyroidism.
Familial states of primary hyperparathyroidism: an update.
J Endocrinol Invest
September 2024
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Background: Familial primary hyperparathyroidism (PHPT) includes syndromic and non-syndromic disorders. The former are characterized by the occurrence of PHPT in association with extra-parathyroid manifestations and includes multiple endocrine neoplasia (MEN) types 1, 2, and 4 syndromes, and hyperparathyroidism-jaw tumor (HPT-JT). The latter consists of familial hypocalciuric hypercalcemia (FHH) types 1, 2 and 3, neonatal severe primary hyperparathyroidism (NSHPT), and familial isolated primary hyperparathyroidism (FIHP).
View Article and Find Full Text PDFPhase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study.
Clin Kidney J
December 2023
Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Background: Upacicalcet is a novel small-molecule calcimimetic agent developed for intravenous injection. Here, we evaluated the long-term efficacy and safety of upacicalcet treatment via intraindividual dose adjustment in haemodialysis patients with secondary hyperparathyroidism (SHPT).
Methods: A phase 2, multicentre, open-label, single-arm study was conducted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!